303 related articles for article (PubMed ID: 25351931)
1. Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats.
Guttman O; Baranovski BM; Schuster R; Kaner Z; Freixo-Lima GS; Bahar N; Kalay N; Mizrahi MI; Brami I; Ochayon DE; Lewis EC
Clin Exp Immunol; 2015 Feb; 179(2):161-72. PubMed ID: 25351931
[TBL] [Abstract][Full Text] [Related]
2. α-1-antitrypsin inhibits acute liver failure in mice.
Jedicke N; Struever N; Aggrawal N; Welte T; Manns MP; Malek NP; Zender L; Janciauskiene S; Wuestefeld T
Hepatology; 2014 Jun; 59(6):2299-308. PubMed ID: 24449466
[TBL] [Abstract][Full Text] [Related]
3. Expanding the clinical indications for α(1)-antitrypsin therapy.
Lewis EC
Mol Med; 2012 Sep; 18(1):957-70. PubMed ID: 22634722
[TBL] [Abstract][Full Text] [Related]
4. Immune-modulating effects of alpha-1 antitrypsin.
Ehlers MR
Biol Chem; 2014 Oct; 395(10):1187-93. PubMed ID: 24854541
[TBL] [Abstract][Full Text] [Related]
5. α-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells.
Ozeri E; Mizrahi M; Shahaf G; Lewis EC
J Immunol; 2012 Jul; 189(1):146-53. PubMed ID: 22634621
[TBL] [Abstract][Full Text] [Related]
6. T Helper Subsets, Peripheral Plasticity, and the Acute Phase Protein, α1-Antitrypsin.
Baranovski BM; Freixo-Lima GS; Lewis EC; Rider P
Biomed Res Int; 2015; 2015():184574. PubMed ID: 26583093
[TBL] [Abstract][Full Text] [Related]
7. α1-Antitrypsin therapy downregulates toll-like receptor-induced IL-1β responses in monocytes and myeloid dendritic cells and may improve islet function in recently diagnosed patients with type 1 diabetes.
Gottlieb PA; Alkanani AK; Michels AW; Lewis EC; Shapiro L; Dinarello CA; Zipris D
J Clin Endocrinol Metab; 2014 Aug; 99(8):E1418-26. PubMed ID: 24527714
[TBL] [Abstract][Full Text] [Related]
8. Commercial α1-antitrypsin preparations markedly differ in their potential to inhibit the ATP-induced release of monocytic interleukin-1β.
Agné A; Richter K; Padberg W; Janciauskiene S; Grau V
Pulm Pharmacol Ther; 2021 Jun; 68():102020. PubMed ID: 33774155
[TBL] [Abstract][Full Text] [Related]
9. Alpha-1 antitrypsin: a potent anti-inflammatory and potential novel therapeutic agent.
Bergin DA; Hurley K; McElvaney NG; Reeves EP
Arch Immunol Ther Exp (Warsz); 2012 Apr; 60(2):81-97. PubMed ID: 22349104
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic compositions and uses of alpha1-antitrypsin: a patent review (2012 - 2015).
Lior Y; Geyra A; Lewis EC
Expert Opin Ther Pat; 2016 May; 26(5):581-9. PubMed ID: 26966859
[TBL] [Abstract][Full Text] [Related]
11. Context-Specific and Immune Cell-Dependent Antitumor Activities of α1-Antitrypsin.
Guttman O; Freixo-Lima GS; Kaner Z; Lior Y; Rider P; Lewis EC
Front Immunol; 2016; 7():559. PubMed ID: 28003813
[TBL] [Abstract][Full Text] [Related]
12. The lipid ties of α1-antitrypsin: Structural and functional aspects.
Segal L; Lewis EC
Cell Immunol; 2022 May; 375():104528. PubMed ID: 35468329
[TBL] [Abstract][Full Text] [Related]
13. Alpha-1 Antitrypsin Deficiency Today: New Insights in the Immunological Pathways.
Baraldo S; Balestro E; Bazzan E; Tiné ME; Biondini D; Turato G; Cosio MG; Saetta M
Respiration; 2016; 91(5):380-5. PubMed ID: 27164860
[TBL] [Abstract][Full Text] [Related]
14. Alpha-1 antitrypsin augmentation therapy corrects accelerated neutrophil apoptosis in deficient individuals.
Hurley K; Lacey N; O'Dwyer CA; Bergin DA; McElvaney OJ; O'Brien ME; McElvaney OF; Reeves EP; McElvaney NG
J Immunol; 2014 Oct; 193(8):3978-91. PubMed ID: 25217166
[TBL] [Abstract][Full Text] [Related]
15. Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release.
Nita I; Hollander C; Westin U; Janciauskiene SM
Respir Res; 2005 Jan; 6(1):12. PubMed ID: 15683545
[TBL] [Abstract][Full Text] [Related]
16. Diabetic retinopathy: could the alpha-1 antitrypsin be a therapeutic option?
Ortiz G; Salica JP; Chuluyan EH; Gallo JE
Biol Res; 2014 Nov; 47():58. PubMed ID: 25723058
[TBL] [Abstract][Full Text] [Related]
17. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with alpha(1)-antitrypsin deficiency (PiZ).
Hill AT; Campbell EJ; Bayley DL; Hill SL; Stockley RA
Am J Respir Crit Care Med; 1999 Dec; 160(6):1968-75. PubMed ID: 10588615
[TBL] [Abstract][Full Text] [Related]
18. Alpha1-antitrypsin inhibits Moraxella catarrhalis MID protein-induced tonsillar B cell proliferation and IL-6 release.
Hadzic R; Nita I; Tassidis H; Riesbeck K; Wingren AG; Janciauskiene S
Immunol Lett; 2006 Feb; 102(2):141-7. PubMed ID: 16214222
[TBL] [Abstract][Full Text] [Related]
19. alpha1-Antitrypsin deficiency: best clinical practice.
Kalsheker NA
J Clin Pathol; 2009 Oct; 62(10):865-9. PubMed ID: 19783716
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic evidence in support of alpha1-antitrypsin as a therapeutic approach for type 1 diabetes.
Fleixo-Lima G; Ventura H; Medini M; Bar L; Strauss P; Lewis EC
J Diabetes Sci Technol; 2014 Nov; 8(6):1193-203. PubMed ID: 25155845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
